Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials.

Literature DB >> 29051280

Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials.

Richard F Schlenk^1,2, Jürgen Krauter³, Emmanuel Raffoux⁴, Karl-Anton Kreuzer⁵, Markus Schaich⁶, Lucien Noens⁷, Thomas Pabst⁸, Madhuri Vusirikala⁹, Didier Bouscary¹⁰, Andrew Spencer¹¹, Anna Candoni¹², Jorge Sierra Gil¹³, Noah Berkowitz¹⁴, Hans-Jochen Weber¹⁵, Oliver Ottmann¹⁶.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：
Panobinostat

Year: 2017 PMID： 29051280 PMCID： PMC5777210 DOI： 10.3324/haematol.2017.172411

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

12 in total

1. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

Authors: Francis Giles; Thomas Fischer; Jorge Cortes; Guillermo Garcia-Manero; Joachim Beck; Farhad Ravandi; Eric Masson; Patricia Rae; Glen Laird; Sunil Sharma; Hagop Kantarjian; Margaret Dugan; Maher Albitar; Kapil Bhalla
Journal: Clin Cancer Res Date: 2006-08-01 Impact factor: 12.531

Review 2. Panobinostat for the treatment of acute myelogenous leukemia.

Authors: Fortunato Morabito; Maria Teresa Voso; Stefan Hohaus; Massimo Gentile; Ernesto Vigna; Anna Grazia Recchia; Lorenzo Iovino; Edoardo Benedetti; Francesco Lo-Coco; Sara Galimberti
Journal: Expert Opin Investig Drugs Date: 2016-08-08 Impact factor: 6.206

Review 3. Relapsed/refractory acute myeloid leukemia: any progress?

Authors: Richard F Schlenk; Carsten Müller-Tidow; Axel Benner; Meinhard Kieser
Journal: Curr Opin Oncol Date: 2017-11 Impact factor: 3.645

4. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

Authors: D J DeAngelo; A Spencer; K N Bhalla; H M Prince; T Fischer; T Kindler; F J Giles; J W Scott; K Parker; A Liu; M Woo; P Atadja; K K Mishra; O G Ottmann
Journal: Leukemia Date: 2013-02-06 Impact factor: 11.528

5. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.

Authors: Mark H Kirschbaum; Kenneth A Foon; Paul Frankel; Christopher Ruel; Bernadette Pulone; Joseph M Tuscano; Edward M Newman
Journal: Leuk Lymphoma Date: 2014-02-24

6. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544

7. Cancer phase I clinical trials: efficient dose escalation with overdose control.

Authors: J Babb; A Rogatko; S Zacks
Journal: Stat Med Date: 1998-05-30 Impact factor: 2.373

8. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.

Authors: P Maiso; E Colado; E M Ocio; M Garayoa; J Martín; P Atadja; A Pandiella; J F San-Miguel
Journal: Leukemia Date: 2009-10-08 Impact factor: 11.528

9. A phase 2 study of vorinostat in acute myeloid leukemia.

Authors: Eric W Schaefer; Arturo Loaiza-Bonilla; Mark Juckett; John F DiPersio; Vivek Roy; James Slack; Wenting Wu; Kristina Laumann; Igor Espinoza-Delgado; Steven D Gore
Journal: Haematologica Date: 2009-10 Impact factor: 9.941

Review 10. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin
Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934

8 in total

1. Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.

Authors: Daniel J DeAngelo; Alison R Walker; Richard F Schlenk; Jorge Sierra; Bruno C Medeiros; Enrique M Ocio; Christoph Röllig; Stephen A Strickland; Felicitas Thol; Sue-Zette Valera; Kohinoor Dasgupta; Noah Berkowitz; Robert K Stuart
Journal: Leuk Res Date: 2019-08-01 Impact factor: 3.156

Review 2. Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.

Authors: Joseph C Rimando; Matthew J Christopher; Michael P Rettig; John F DiPersio
Journal: J Clin Oncol Date: 2021-01-12 Impact factor: 44.544

Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials.

1. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

Review 2. Panobinostat for the treatment of acute myelogenous leukemia.

Review 3. Relapsed/refractory acute myeloid leukemia: any progress?

4. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

5. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.

6. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

7. Cancer phase I clinical trials: efficient dose escalation with overdose control.

8. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.

9. A phase 2 study of vorinostat in acute myeloid leukemia.

Review 10. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

1. Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.

Review 2. Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.

Review 3. Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects.

Review 4. HDAC Inhibitors in Acute Myeloid Leukemia.

Review 5. Histone Deacetylases and their Inhibitors in Cancer Epigenetics.

Review 6. Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies.

Review 7. Differentiation therapy of myeloid leukemia: four decades of development.

8. MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia.